Tsumura & Co (TSMRF) AI Stock Analysis

Top Page

Tsumura & Co

(Other OTC:TSMRF)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Multi-year revenue expansionThe multi-year revenue increase indicates sustained demand for Tsumura’s kampo portfolio and expanding commercial scale. Continued adoption through Japan’s healthcare system can support the company’s core prescription-led model over the medium term.

Negative Factors

Negative free cash flowWeak cash conversion and negative free cash flow reduce the funds available for debt reduction, dividends, and strategic investment. If sustained, this gap could limit financial flexibility even though reported profitability remains strong.

Tsumura & Co (TSMRF) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $1.73B
Dividend Yield: 4.30%
Average Volume (3M): ―
Price to Earnings (P/E): 9.4
Beta (1Y): -0.10
Revenue Growth: 7.01%
EPS Growth: 17.20%
Country: US
Employees: 4,923
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Tsumura & Co Business Overview & Revenue Model

Company Description

Established in Tokyo, Japan, in 1893, Tsumura & Co. operates worldwide in the pharmaceutical sector. The company's core business involves the creation and international distribution of various medicinal products, with a particular focus on Kampo extr...

Tsumura & Co Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

TSMRF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JP:4516	73Outperform	JPY 231.43B	7.33	―	3.61%	12.23%	3.35%
JP:4534	68Neutral	JPY 111.78B	12.67	6.64%	2.51%	14.72%	52.55%
JP:4521	65Neutral	JPY 137.95B	14.06	6.94%	4.96%	-6.86%	-17.71%
JP:2929	59Neutral	JPY 18.40B	9.29	―	3.46%	-3.12%	406.78%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

TSMRF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TSMRF	Tsumura & Co	23.53	1.29	5.79%
JP:4521	Kaken Pharmaceutical Co	3830.00	333.78	9.55%
JP:4534	Mochida Pharmaceutical Co., Ltd.	3285.00	406.97	14.14%
JP:2929	Pharma Foods International Co., Ltd.	635.00	-129.75	-16.97%
JP:4516	Nippon Shinyaku Co., Ltd.	3436.00	308.38	9.86%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Tsumura & Co AI Stock Analysis